increases didanosine absorption (69% rise in the maximum serum
levels). In some patients the dosage of didanosine has been halved without the loss of antiviral efficacy
If the dose of didanosine is not reduced, there is the potential for an increase in didanosine adverse effects. The UK manufacturer recommends close monitoring for adverse effects but the US manufacturer advises against concurrent use.